Skip to Content

Generic Samsca Availability

Samsca is a brand name of tolvaptan, approved by the FDA in the following formulation(s):

SAMSCA (tolvaptan - tablet;oral)

Has a generic version of Samsca been approved?

No. There is currently no therapeutically equivalent version of Samsca available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Samsca. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Benzoheterocyclic compounds
    Patent 5,753,677
    Issued: May 19, 1998
    Inventor(s): Ogawa; Hidenori & Miyamoto; Hisashi & Kondo; Kazumi & Yamashita; Hiroshi & Nakaya; Kenji & Komatsu; Hajime & Tanaka; Michinori & Kora; Shinya & Tominaga; Michiaki & Yabuuchi; Yoichi
    Assignee(s): Otsuka Pharmaceutical Co., Ltd.

    Novel benzoheterocyclic compounds of the formula: ##STR1## which have excellent vasopressin antagonistic activities and are useful as vasodilator, hypotensive agent, water diuretics, platelet agglutination inhibitor, and a vasopressin antagonistic composition containing the compound as the active ingredient.

    Patent expiration dates:

    • May 19, 2020
  • Process for preparing benzazepine compounds or salts thereof
    Patent 8,501,730
    Issued: August 6, 2013
    Assignee(s): Otsuka Pharmaceutical Co., Ltd.

    This invention provides a process for preparing benzazepine compounds of the formula (1): wherein X1 is a halogen atom, R1 and R2 are a lower alkyl group, or salts thereof as well as intermediate benzoic acid compounds in high yield and high purity on industrial scale, which are useful as an intermediate for preparing a pharmaceutically active 2,3,4,5-tetrahydro-1H-1-benzazepine compound having vasopressin antagonistic activity.

    Patent expiration dates:

    • September 1, 2026
      Drug substance

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.